A228760 Stock Overview
Genomictree Inc., a biomarker-based molecular diagnostics company, develops and commercializes molecular diagnostic products for the detection of cancer and various infectious diseases.
No risks detected for A228760 from our risk checks.
Genomictree Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||₩9,130.00|
|52 Week High||₩14,600.00|
|52 Week Low||₩8,310.00|
|1 Month Change||0.33%|
|3 Month Change||-17.38%|
|1 Year Change||-25.16%|
|3 Year Change||-57.63%|
|5 Year Change||20.93%|
|Change since IPO||102.89%|
Recent News & Updates
|A228760||KR Biotechs||KR Market|
Return vs Industry: A228760 exceeded the KR Biotechs industry which returned -40.8% over the past year.
Return vs Market: A228760 underperformed the KR Market which returned -19.7% over the past year.
|A228760 Average Weekly Movement||4.6%|
|Biotechs Industry Average Movement||8.1%|
|Market Average Movement||6.6%|
|10% most volatile stocks in KR Market||11.6%|
|10% least volatile stocks in KR Market||3.9%|
Stable Share Price: A228760 is less volatile than 75% of KR stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: A228760's weekly volatility (5%) has been stable over the past year.
About the Company
Genomictree Inc., a biomarker-based molecular diagnostics company, develops and commercializes molecular diagnostic products for the detection of cancer and various infectious diseases. The company offers EarlyTect C, a screening method for early diagnosis of colorectal cancer; EarlyTect L for detection of epigenetic markers associated with lung cancer in pulmonary nodule patients; and EarlyTect B for detection of genetic and epigenetic markers associated with bladder cancer in hematuria patients. It also provides AccuraTect-KRAS and AccuraTect-BRAF that are companion diagnostics for colorectal cancer; AccuraTect-EGFR, a companion diagnostic for lung cancer; and AccuraDTect SARS-CoV-2 RT-qPCR kits, as well as test providers.
Genomictree Inc. Fundamentals Summary
|A228760 fundamental statistics|
Is A228760 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|A228760 income statement (TTM)|
|Cost of Revenue||₩5.02b|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-218.83|
|Net Profit Margin||-14.65%|
How did A228760 perform over the long term?See historical performance and comparison